Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

 Samsung Bioepis Initiates P-III Clinical Trial of SB17 Proposed Biosimilar to Stelara (ustekinumab)

C-Bridge Capital Signs a Development & Commercialization Agreement with Samsung Bioepis for Biosimilars in China

Shots:

  • The company initiates P-III clinical trial to evaluate the efficacy, safety, tolerability, PK, and immunogenicity of SB17 vs Stelara in a ratio (1:1) in patients with moderate to severe plaque psoriasis
  • Additionally, patients either continue on Stelara or transition to SB17 @28wks. The IPs (SB17 or Stelara, q12w) will be administered @0, 4 and for up to 40wks. and the last assessment will be performed @52wks.
  • The company continues to advance a broad pipeline of biosimilar candidates covering therapeutic areas, including immunology, oncology, ophthalmology, hematology, endocrinology, and gastroenterology

Click here to read full press release/ article | Ref:  Samsung Bioepis | Image: PR Newswire

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post